// App-Quantinova.ai

5068 : Androgen receptor (AR) amplification in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) and enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

Researchers

Presenter

  • Rahul Raj Aggarwal

Principal Investigators

  • Jack Youngren

  • Josh Stuart

  • Joshi J. Alumkal

  • Alexandria Toschi

  • Nicole Zona

  • Robert Evan Reiter

  • Primo Lara

  • Kim N. Chi

  • Pamela Paris

  • Tomasz M. Beer

  • Charles J. Ryan

  • Owen Witte

  • Christopher P. Evans

  • Martin Edwin Gleave

  • Eric Jay Small

  • Adam Foye

  • Susan Olson

Medical Centers

  • Oregon Health and Science University, Portland, OR

  • UC Davis, Sacramento, CA

  • OHSU, Portland, ORUC Davis Comprehensive Cancer Center, Sacramento, CABC Cancer Agency, Vancouver, BC, Canada

  • Oregon Health & Science University, OHSU Knight Cancer Institute, Portland, OR

  • Vancouver Prostate Centre, Vancouver, BC, Canada

  • UCLA, Los Angeles, CA

  • UC Santa Cruz, Santa Cruz, CA

  • UC San Francisco, San Francisco, CA

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Androgen receptor

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved